Literature DB >> 15869992

High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.

Antoine Valeri1, Gaelle Fromont, Wael Sakr, Rahmène Azzouzi, Jyotirmoy Dey, Karine Chantrel-Groussard, Alain Latil, Philippe Berthon, Olivier Cussenot, J Edson Pontes, Michael L Cher.   

Abstract

Loss of heterozygosity (LOH) is the most consistent genetic change in prostate cancer (CaP). We aimed, to correlate specific LOH and the overall LOH frequency, to disease progression after radical prostatectomy (RP) in high-grade CaP. Between January 1990 through December 1998, 126 patients who underwent RP (cT1-T2), Gleason 8-10, were pT3, or pN1, or SM(+) (surgical margins). Nine were lost of follow-up, 39/117 (33%) had no biochemical progression (mean follow-up: 45 months). After exclusion for preoperative PSA >50 ng/mL, a case-control study was designed by matching 26 of these cases with 26 similar patients without biochemical progression (criteria: pT, pN, year of surgery). Using microsatellite markers, LOH were assessed on six chromosomal regions (7q31, 8p22, 12p13, 13q14, 16q23.2, 18q21). No prognostic value was associated with LOH at any one specific locus. However, the overall LOH frequency (five classes, cutoff of 60%), was significantly higher if progression (P = 0.02; P = 0.03) in SM(+) patients, and was near statistical significance (P = 0.08; P = 0.07) for the overall case-control population. In multivariate analysis (overall population), the overall LOH rate > or =60% was independently associated with progression [P = 0.035; Odds Ratio (OR) = 5.54]. An overall LOH rate > or =60% predicted poor outcome in 85% of SM(+) patients and 69% of the whole population. Our results suggest that the overall rate of LOH at chromosomal "hot spots" is more likely to be predictive of recurrence than the presence of LOH at any one particular locus. Moreover, the identification of a threshold of LOH could help in predicting patients with poor outcome who may be candidates for local or systemic adjuvant therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15869992     DOI: 10.1016/j.urolonc.2004.08.015

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  2 in total

1.  ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.

Authors:  Sanna Siltanen; Kirsi Syrjäkoski; Rainer Fagerholm; Tarja Ikonen; Peter Lipman; Jacob Mallott; Kaija Holli; Teuvo L J Tammela; Heikki J Järvinen; Jukka-Pekka Mecklin; Kristiina Aittomäki; Carl Blomqvist; Joan E Bailey-Wilson; Heli Nevanlinna; Lauri A Aaltonen; Johanna Schleutker; Pia Vahteristo
Journal:  Eur J Hum Genet       Date:  2008-03-12       Impact factor: 4.246

2.  Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Authors:  Sanna Siltanen; Tiina Wahlfors; Martin Schindler; Outi R Saramäki; John Patrick Mpindi; Leena Latonen; Robert L Vessella; Teuvo L J Tammela; Olli Kallioniemi; Tapio Visakorpi; Johanna Schleutker
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.